Alexander Xenakis

Alex Xenakis, on behalf of Kripa Devarakonda, asked if there is an option to modify the MYQORZO REMS requirements in the future with updated post-marketing data to potentially make it more favorable.

Answer

Robert Blum, President and CEO, and Fady Malik, EVP of R&D, confirmed that real-world evidence could inform future REMS modifications, citing the precedent of Camzyos. They are not guiding to near-term changes but will assess potential 'pinch points' with real-world data.

Alexander Xenakis from Truist Securities asked about Absci's long-term value proposition and competitive strategy, considering that many large pharmaceutical companies are developing their own internal AI-based drug discovery systems.

Answer

CEO Sean McClain explained that Absci's key differentiator is its focus on de novo AI design for traditionally hard-to-drug targets, such as GPCRs and ion channels. He highlighted the recent success with partner Almirall on a difficult ion channel target, which led to the selection of a second bispecific target, as proof of their unique value proposition that attracts major pharma interest.

Alexander Xenakis from Truist Securities asked about Absci's long-term competitive value proposition, considering that large pharma companies have their own internal AI drug discovery platforms.

Answer

CEO Sean McClain highlighted Absci's key differentiator as its focus on de novo AI design for difficult-to-drug targets like GPCRs and ion channels. He pointed to the successful Almirall partnership, which validated their approach on a difficult ion channel target and led to a second program election, as evidence of their unique value proposition.

Alexander Xenakis of Truist Securities asked if Absci anticipates improved economics on future partnerships as its assets advance and inquired about the flexibility of its cost structure to adapt to market conditions.

Answer

CFO & CBO Zachariah Jonasson addressed both questions. He affirmed they expect enhanced deal terms, driven by clinical progress and the platform's ability to address challenging targets. Regarding costs, Jonasson explained they continually seek efficiencies through the AI platform, allowing for resource reallocation and cost reductions, a process they evaluate quarterly.